Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.71 |
| ▸ | ABL1 | P00519 | 8/20 | 0.71 |
| ▸ | EGFR | P00533 | 8/20 | 0.71 |
| ▸ | ABL2 | P42684 | 8/20 | 0.71 |
| ▸ | LCK | P06239 | 2/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | HCK | P08631 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107249 | 0.94 | SRC (0.80) | SRCABL1EGFRABL2LCK | |
| SCHEMBL7023713 | 0.91 | SRC (0.72) | SRCABL1EGFRABL2LCK | |
| SCHEMBL7016556 | 0.91 | SRC (0.61) | SRCABL1EGFRABL2LCK | |
| SCHEMBL8098913 | 0.90 | SRC (0.63) | SRCABL1EGFRABL2LCK | |
| SCHEMBL8108098 | 0.89 | SRC (0.62) | SRCABL1EGFRABL2LCK | |
| SCHEMBL7023786 | 0.89 | ABL1 (0.89) | SRCABL1EGFRABL2LCK | |
| SCHEMBL7017737 | 0.86 | SRC (0.58) | SRCABL1EGFRABL2LCK | |
| SCHEMBL8108273 | 0.85 | SRC (0.70) | SRCABL1EGFRABL2LCK | |
| SCHEMBL7020164 | 0.84 | SRC (0.81) | SRCABL1EGFRABL2LCK | |
| SCHEMBL7017312 | 0.84 | SRC (0.65) | SRCABL1EGFRABL2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |